Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

What foods to eat and avoid for optimal results. Whether you've been prescribed Mounjaro (tirzepatide) for type 2 diabetes, ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Private Capital Advisors Inc. grew its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 0.1% during ...

Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales ...

RFG Advisory LLC boosted its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 13.4% in the fourth quarter, ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...